{'fraction_non_alphanumeric': 0.03487064116985377, 'fraction_numerical': 0.025871766029246346, 'mean_word_length': 4.779220779220779, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Microencapsulation of human insulin DEAE-dextran complex and the complex in liposomes by the emulsion non-solvent addition method.

Human insulin-DEAE (diethyl amino ethyl) dextran complex and human insulin DEAE-dextran complex in liposomes were encapsulated in cellulose acetate butyrate (CAB) microcapsules by the emulsion non-solvent addition method. The ratio of core-to-coat used was 1:1. The average diameters of the complex microcapsules and the complex liposome microcapsules were 239.5 +/- 77.5 and 182.9 +/- 52.2 microns respectively. In vitro dissolution studies of both types of microcapsules in simulated intestinal fluid at pH 7.2 showed a sustained release of the complex and the complex liposome microcapsules with t50 = 1.5 h and 4 h respectively. This study can be applied to the further development of oral formulations of human insulin liposomes for diabetic treatment.